CAMBRIDGE, Mass. — Fable Therapeutics has appointed David J. Baker, Ph.D., as its new Chief Scientific Officer, the company announced Tuesday. Baker will lead the biotech firm’s scientific strategy and oversee advancement of its pipeline of biologics developed through structure- and sequence-based protein language models.
Baker brings significant experience in drug discovery, most recently serving as Head of Metabolism Bioscience for Cardiovascular, Renal, and Metabolism (CVRM) at AstraZeneca. There, he was responsible for guiding metabolic disease programs from target selection through Phase 2b trials in areas including diabetes, obesity, MASH, and dyslipidemia.
“David’s extensive experience in drug discovery, with a strong track record of high performance and scientific leadership across the cardio-metabolic therapeutic area, makes him an ideal leader to advance our portfolio,” said Geoff MacKay, President and CEO of Fable Therapeutics.
At Fable, Baker will oversee the company’s research efforts from discovery through Investigational New Drug (IND) applications and first-in-human clinical trials. The company is focused on developing purpose-built biologics using advanced computational technologies to address high-impact diseases.
“I’m thrilled to be joining such a groundbreaking company with extremely talented individuals and looking forward to bringing new therapies to patients,” Baker said.
